Institute of Biomedicine, University of Turku, Turku, Finland.
Finnish Institute for Health and Welfare, Helsinki, Finland.
Nat Commun. 2022 May 5;13(1):2476. doi: 10.1038/s41467-022-30162-5.
Two COVID-19 mRNA (of BNT162b2, mRNA-1273) and two adenovirus vector vaccines (ChAdOx1 and Janssen) are licensed in Europe, but optimization of regime and dosing is still ongoing. Here we show in health care workers (n = 328) that two doses of BNT162b2, mRNA-1273, or a combination of ChAdOx1 adenovirus vector and mRNA vaccines administrated with a long 12-week dose interval induce equally high levels of anti-SARS-CoV-2 spike antibodies and neutralizing antibodies against D614 and Delta variant. By contrast, two doses of BNT162b2 with a short 3-week interval induce 2-3-fold lower titers of neutralizing antibodies than those from the 12-week interval, yet a third BNT162b2 or mRNA-1273 booster dose increases the antibody levels 4-fold compared to the levels after the second dose, as well as induces neutralizing antibody against Omicron BA.1 variant. Our data thus indicates that a third COVID-19 mRNA vaccine may induce cross-protective neutralizing antibodies against multiple variants.
两种 COVID-19 mRNA（BNT162b2、mRNA-1273）疫苗和两种腺病毒载体疫苗（ChAdOx1 和 Janssen）在欧洲获得许可，但方案和剂量的优化仍在进行中。在这里，我们在医护人员（n=328）中表明，两剂 BNT162b2、mRNA-1273 或 ChAdOx1 腺病毒载体和 mRNA 疫苗联合使用长达 12 周的间隔剂量，可诱导同样高水平的抗 SARS-CoV-2 刺突抗体和针对 D614 和 Delta 变体的中和抗体。相比之下，两剂 BNT162b2 间隔 3 周的间隔诱导的中和抗体滴度比 12 周间隔低 2-3 倍，但第三剂 BNT162b2 或 mRNA-1273 加强针可将抗体水平提高 4 倍，与第二剂后的水平相比，也可诱导针对奥密克戎 BA.1 变体的中和抗体。因此，我们的数据表明，第三剂 COVID-19 mRNA 疫苗可能会诱导针对多种变体的交叉保护中和抗体。
